T3D Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
Phase 2
Not yet recruiting
- Conditions
- Alzheimer's Disease
- Interventions
- Other: Placebo Comparator
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT06964230
- Locations
- 🇺🇸
T3D Therapeutics, Inc., Durham, North Carolina, United States
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: PlacebosDrug: 15mg T3D-959Drug: 30 mg T3D-959Drug: 45 mg T3D-959
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04251182
- Locations
- 🇺🇸
T3D Therapeutics, Durham, North Carolina, United States
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- T3D Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02560753
- Locations
- 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸Miami Jewish Health Systems, Miami, Florida, United States
🇺🇸New Hope Clinical Research, Charlotte, North Carolina, United States
News
No news found